Diagnosis and treatment of peripheral arterial disease: recommendations for the medical practice in Belgium.

Belgium; Comorbidity; Coronary Disease/epidemiology; Diabetic Angiopathies/epidemiology; Foot/blood supply; Humans; Hyperlipidemias/epidemiology; Intermittent Claudication/diagnosis; Kidney Diseases/epidemiology; Obesity/epidemiology; Odds Ratio; Peripheral Vascular Diseases/diagnosis/epidemiology/therapy; Platelet Aggregation Inhibitors/therapeutic use; Prevalence; Regional Blood Flow; Risk Factors; Smoking/epidemiology

Disciplines :

Surgery

Author, co-author :

Clement, Denis

Kolh, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Service d'Informations médico économiques (SIME)

Motte, Serge

Sprynger, Muriel ; Centre Hospitalier Universitaire de Liège - CHU > Cardiologie

Van Damme, Hendrik ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie cardio-vasculaire

Verhamme, Peter

Vermassen, Frank

Wautrecht, Jean*-Claude

Language :

English

Title :

Diagnosis and treatment of peripheral arterial disease: recommendations for the medical practice in Belgium.

Publication date :

2007

Journal title :

Acta Chirurgica Belgica

ISSN :

1784-3421

eISSN :

2577-0160

Publisher :

Acta Medica Belgica, Bruxelles, Belgium

Volume :

107

Issue :

Pages :

595-604

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 25 February 2011

Statistics

Number of views

169 (2 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

TASC. Management of peripheral arterial disease (PAD). Trans-Atlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg, 2000, 19 (Suppl A): Siexxviii. S1-S250.
TASC. Management of Peripheral Arterial Disease (PAD) TransAtlantic Intersociety Consensus (TASC). J Vasc Surg, 2000, 31 (1 part 2): S1-S287.
TASC. Management of peripheral arterial disease (PAD). Trans-Atlantic Inter-Society Consensus (TASC). Int Angiol, 2000, 19 (1 Suppl. 1): IeXXIV. 1-304.
TASC II NORGREN L., HYATT W. R., DORMANDY M. R. et al. on behalf of the TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg, 2007, 33 (Suppl 1): S1-S75.
CRIQUI M. H., FRONEK A., BARRETT-C ONNOR E., KLAUBER LAUBER M. R., GOODMAN D. The prevalence of peripheral arterial disease in a defined population. Circulation, 1985, 71 (3): 510-551.
HIATT W. R., HOAG S., HAMMAN R. F. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation, 1995, 91 (5): 1472-1479.
SELVIN E., ERLINGER T. P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation, 2004, 110 (6): 738-743.
FOWKES F. G., HOUSLEY E., CAWOOD E. H., MACINTYRE C. C., RUCKLEY C. V., PRESCOTT R. J. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991, 20 (2): 384-392.
HIRSCH A., CRIQUI M., TREATJACOBSON D., REGENSTEINER J., CREAGER M., OLIN J. et al. Peripheral arterial disease detection, awareness, and treatment in primary care (PARTNERS). JAMA, 2001, 286(11): 1317-1324.
KULLO I. J., BAILEY K. R., KARDIA S. L., MOSLEY Jr. T. H., BOERWINKLE E., TURNER S. T. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vasc Med. 2003, 8 (4): 237-242.
MUNTNER P., WILDMAN R. P., REYNOLDS K., DESALVO K. B., CHEN J., FONSECA V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care, 2005, 28 (8): 1981e-987.
ADA. Peripheral arterial disease in people with diabetes. Diabetes Care, 2003, 26 (12): 3333-3341.
RIDKER P.M., STAMPFER M. J., RIFAI N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteinc, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA, 2001, 285 (19): 2481-2485.
NOGUES M., PEDRO-BOTET J., RUBIES-PRAT J., VIDALBARRAQUER F. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation. 1992, 85 (1): 30-36.
O'HARE A.M., VITTINGHOFFE E., HSIA J., SHLIPAK M. G. Renal insuffiiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol, 2004, 15 (4): 1046-1051.
STEG PH. G., BHATT D. L., WILSON P. W. F. et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA, 2007, 297 (11): 1197-1206.
LENG G. C., FOWKES F. G. R. The Edinburgh Claudication Questionnaire: an improved version of the version of the WHO/ROSE questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992. Vol. 45, No. 10. pp. 1101-1109.
TONSTAD S., FARSANG C., KLAENE G., LEWIS K., MANOLIS A., PERRUCHOUD A. P. et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre. randomized study. Ear Heart. J. 2003, 24 (10): 946-955.
DE BACKER G., AMBROSIONI E., BORCH-JOHNSEN K., BROTONS C., CIFKOVA R., DALLONGEVILLE J. et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis, 2004, 173 (2): 381-391.
GRUNDY S. M., CLEEMAN J. I., MERZ C. N., BREWER Jr. H. B., CLARK L. T. HUNNINGHAKE D. B. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 2004, 110 (2): 227-239.
HIRSCH A. T., HASKAL Z. J., HERTZER N. R., BAKAL C. W., CREAGER M. A., HALPERIN J. L. et al. ACC/AHA, 2005 guidelines for the management of patients with peripheral arterial disease (lower extermity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interverntions. Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, National Heart, Lung, and Blood Institute, Society for Vascular Nursing, TransAtlantic Inter-Society Consensus, and Vascular Disease Foundation. J Am Coll Cardiol, 2006, 47: 1239-1312.
Heart Protection Study Collaborative Group Randomized trial of the effects of cholesterol lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg, 2007, 45: 645-54.
CHOBANIAN A. V., BAKRIS G. L., BLACK H. R., CUSHMAN W. C., GREEN L. A., IZZO Jr. J. L. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003, 42 (6): 1206-1252.
Guidelines for the management of arterial Hypertension. European Heart Journal, 2007, 28: 1462-1536.
YUSUF S., SLEIGHT P., POGUE J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342 (3): 145-53.
RADACK K., DECK C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med, 1991, 151 (9): 1769-1776.
ADA. Standards of medical care in diabetese 2006. Diabetes Care, 2006, 29 (Suppl. 1): S4-S42.
DORMANDY J. A., CHARBONNEL B., ECKLAND D. J., ERDMANN E., MASSIBENEDETTI U. K. P. D. S. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352 (9131): 837-853.
MOULES M. I. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005, 366 (9493): 1279-1289.
ATC. Collaborative meta-analysis of randomised trials of antiplatelct therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002, 324 (7329): 71-86.
Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med, 2007, 261: 276-284.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996, 348 (9038): 1329-39.
DEEPAK L. B. et al. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Alherothrombotic Events. N Engl J Med, 2006, 354: 1706-17.
Guidelines of the French Society for Digestive. Endoscopy (SPED) - Management of Patients on Anticoagulants or Antiplatelet Agents before Digestive Endoscopy. Endoscopy. 2006, 38 (6): 632-638.
Prise en charge des patienls sous agents antiplaquettaires en odontostomatologie Recommandations SOCIÉTÉ FRANCOPHONE DE MÉDECINE BUCCALE ET DE CHIRURGIE BUCCALE Médecine Buccale Chirurgie Buccale Vol 11, 2005, 55-76.
Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. British Journal of Anaesthesia, 2006, 97 (4): 580-5.
HIATT W., WOLFEL E., MEIER R., REGENSTEINER J. Superiority of treadmill walking exercise vs. strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation, 1994, 90: 1866-1874.
LEHERT P., COMTE S., GAMAND S., BROWN T. M. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol, 1994, 23 (Suppl. 3): S48-S52.
AHIMASTOS A., LAWLER A., REID C., PETER A., BLOMBERY and KINGWELL A. Brief Communication: Ramipril Markedly Improves Walking Ability in Patients with Peripheral Arterial Disease. A Randomized Trial. Ann Intern Med, 2006. 144: 660-664.